Liquid Biopsy Diagnostics Market - Strategic Insights and Forecasts (2026-2031)

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

8. 3.8. Product Pipeline Analysis

9. 3.9. Incidence and Prevalence Analysis

10. 3.10. Patent Analysis

4. TECHNOLOGICAL OUTLOOK

5. LIQUID BIOPSY DIAGNOSTICS MARKET BY PRODUCT TYPE

1. 5.1. Introduction

2. 5.2. Kits & Reagents

3. 5.3. Instruments

4. 5.4. Services

6. LIQUID BIOPSY DIAGNOSTICS MARKET BY BIOMARKER TYPE

1. 6.1. Introduction

2. 6.2. Circulating Tumor Cells (CTCs)

3. 6.3. Circulating Tumor DNA (ctDNA)

4. 6.4. Extracellular Vesicles (EVs)

5. 6.5. Cell-Free DNA (cfDNA)

7. LIQUID BIOPSY DIAGNOSTICS MARKET BY TECHNOLOGY

1. 7.1. Introduction

2. 7.2. Next-Generation Sequencing (NGS)

3. 7.3. Polymerase Chain Reaction (PCR)

4. 7.4. Microarray

5. 7.5. Digital PCR

8. LIQUID BIOPSY DIAGNOSTICS MARKET BY APPLICATION

1. 8.1. Introduction

2. 8.2. Cancer Diagnosis

3. 8.3. Therapy Selection

4. 8.4. Treatment Monitoring

5. 8.5. Recurrence Monitoring

9. AI-BASED RESIDUAL VALUE PREDICTION MARKET BY GEOGRAPHY

1. 9.1. Introduction

2. 9.2. North America

   1. 9.2.1. USA

   2. 9.2.2. Canada

   3. 9.2.3. Mexico

3. 9.3. South America

   1. 9.3.1. Brazil

   2. 9.3.2. Argentina

   3. 9.3.3. Others

4. 9.4. Europe

   1. 9.4.1. United Kingdom

   2. 9.4.2. Germany

   3. 9.4.3. France

   4. 9.4.4. Spain

   5. 9.4.5. Others

5. 9.5. Middle East and Africa

   1. 9.5.1. Saudi Arabia

   2. 9.5.2. UAE

   3. 9.5.3. Others

6. 9.6. Asia Pacific

   1. 9.6.1. China

   2. 9.6.2. India

   3. 9.6.3. Japan

   4. 9.6.4. South Korea

   5. 9.6.5. Indonesia

   6. 9.6.6. Thailand

   7. 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 10.1. Major Players and Strategy Analysis

2. 10.2. Market Share Analysis

3. 10.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 10.4. Competitive Dashboard

11. COMPANY PROFILES

1. 11.1. Guardant Health

2. 11.2. Roche Diagnostics

3. 11.3. Illumina

4. 11.4. Thermo Fisher Scientific

5. 11.5. QIAGEN

6. 11.6. Bio-Rad Laboratories

7. 11.7. Exact Sciences

8. 11.8. Freenome

9. 11.9. GRAIL

10. 11.10. Agilent Technologies

12. APPENDIX

1. 12.1. Currency

2. 12.2. Assumptions

3. 12.3. Base and Forecast Years Timeline

4. 12.4. Key benefits for the stakeholders

5. 12.5. Research Methodology

6. 12.6. Abbreviations

LIST OF FIGURES

LIST OF TABLES